Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;32(12):1052-1057.
doi: 10.1097/IJG.0000000000002327. Epub 2023 Oct 19.

Short-Term Efficacy and Safety of Phacoemulsification Associated With iStent Inject W in Patients With Controlled Open Angle Glaucoma

Yanis Louanchi  1   2   3   4 , Emmanuelle Brasnu  1   5 , Pascale Hamard  1   5 , Vittoria Aragno  2 , Christophe Baudouin  1   5   6   2 , Antoine Labbé  1   5   6   2
Affiliations

Short-Term Efficacy and Safety of Phacoemulsification Associated With iStent Inject W in Patients With Controlled Open Angle Glaucoma

Yanis Louanchi et al. J Glaucoma. .

Abstract

Prcis: The iStent inject W implanted during phacoemulsification effectively reduces IOP.

Purpose: The purpose of this study was to evaluate the efficacy and safety of iStent inject W combined with phacoemulsification in patients with controlled open angle glaucoma undergoing cataract surgery.

Patients and methods: We conducted a retrospective, bicentric study of patients with controlled chronic open angle glaucoma who underwent phacoemulsification combined with the injection of 2 iStent inject Ws. Patient characteristics, including intraocular pressure (IOP) and the number of glaucoma medications, were evaluated preoperatively and 1 week, 1 month, and 6 months postoperatively. The primary end point was IOP reduction, and the secondary end point was the reduction in the number of glaucoma medications.

Results: In this study, 85 eyes were included. The majority of patients had primary open angle glaucoma (85% of eyes). Preoperative mean IOP was 16.1±2.0 mm Hg with a mean of 2.3±0.5 glaucoma medications. At 1 week postoperatively, the mean IOP was 16.7±3.1 mm Hg with a mean of 2.0±0.7 hypotensive medications. At 1 and 6 months, the mean IOP was 14.2±2.1 and 13.0±1.5 mm Hg, with a mean of 2.0±0.6 and 1.8±0.5 glaucoma medications, respectively. The percentage IOP reduction at 1 and 6 months was 11.6% ( P =0.001) and 19.3% ( P <0.0001), respectively. Regarding glaucoma medications, at 1 and 6 months, the reduction in the number of medications was 12.9% ( P =0.025) and 22.4% ( P =0.003), respectively. The most frequent significant postoperative adverse events were corneal edema in 7%, IOP spikes in 6%, and hyphema in 6% of eyes, which resolved spontaneously.

Conclusions: The iStent inject W implanted during phacoemulsification effectively reduces IOP and the number of glaucoma medications needed at 6 months of follow-up, with a favorable safety profile in patients with controlled open angle glaucoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: where is the evidence? Asia Pac J Ophthalmol (Phila). 2020;9:203–214.
    1. Buffet J, Brasnu E, Baudouin C, et al. Efficacy of 2 trabecular Micro-Bypass Stents during phacoemulsification for mild to advanced primary open-angle glaucoma controlled with topical hypotensive medications. J Glaucoma. 2017;26:1149–1154.
    1. Ferguson TJ, Mechels KB, Dockter Z, et al. iStent Trabecular Microbypass Stent implantation with phacoemulsification in patients with open-angle glaucoma: 6-year outcomes. OPTH. 2020;14:1859–1866.
    1. Salimi A, Clement C, Shiu M, et al. Second-generation trabecular Micro-Bypass (iStent inject) with cataract surgery in eyes with normal-tension glaucoma: one-year outcomes of a multi-centre study. Ophthalmol Ther. 2020;9:585–596.
    1. Salimi A, Watt H, Harasymowycz P. Three-year outcomes of second-generation trabecular Micro-bypass Stents (iStent inject) with phacoemulsification in various glaucoma subtypes and severities. J Glaucoma. 2021;30:266–275.